StreetAlpha.app
Home › Stocks › IFRX

InflaRx N.V. (IFRX)

Healthcare
$1.04
▼ −4.59%
LAST CLOSE · NOV 20

InflaRx develops drugs that block the inflammatory protein C5a, with vilobelimab sold to hospitals for COVID-19 patients. It last closed at $1.04 on Nov 20, down 4.59% on the day.

AI Auto Pilots
Is IFRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IFRX.

Key Stats

Last 12 months
Results
Revenue
EUR 29K
−82.3% vs a year ago
Net income
−EUR 45.6M
−155582.1% margin
Gross margin
−24677.9%
−EUR 7.2M gross profit
Balance sheet
Cash & equivalents
EUR 16.0M
At Dec 31
Shareholder equity
EUR 41.6M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: EUR 63KEUR 63KFY2023FY2024: EUR 166KEUR 166KFY2024FY2025: EUR 29KEUR 29KFY2025

From IFRX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 20). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on file yet
Reported EPS
—
Quarter ended Jun 2025
Year ago EPS
—
Same quarter last year
Revenue
$39,432
+520.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Jun 2024: $6,357Jun '24Jun 2025: $39,432Jun '25Latest $39,432
StreetAlpha's call on IFRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IFRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IFRX

Technical Analysis

IFRX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 32% below its 20 day and 53% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot S1 at $1.01, and the nearest resistance the Pivot at $1.06.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.4%/day
Key levels
$2.9552 week high+183.7%
$1.80100 day average+73.1%
$1.66200 day average+59.6%
$1.61Swing high (Oct 20)+54.8%
$1.5950 day average+52.9%
$1.3820 day average+32.7%
$1.09Pivot R1+4.8%
$1.06Pivot+1.9%
$1.04Last close
$1.01Pivot S1−2.9%
$0.8052 week low−23.1%
Indicators
RSI (14)26.67Oversold below 30Oversold
MACD-0.15Below its signal lineBearish
Stochastic4.1Near the bottom of its rangeOversold
ADX (14)32.5Trending down
Williams %R-98.5Oversold below −80, overbought above −20Oversold
CCI (20)-100.0Oversold below −100, overbought above 100Neutral
Rate of change−20.3%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 12.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IFRX

What happened before

See how IFRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IFRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IFRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IFRXHow many large options trades hit IFRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

IFRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲35 buying vs 22 selling
  • ▲Shares held by funds +3.5%
  • ▲Funds holding +2
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding6462+3.2%
In funds' top 1000–
Held by funds–––
New / increased12 / 2330 / 13−18.6%
Reduced / sold out13 / 97 / 3+120.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IFRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IFRX is in one of them and how their past IFRX trades turned out.

IFRX in the AI portfolios
Loading…

IFRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IFRX in an article yet. Here's the latest on the wider market.

IFRX in the news

About InflaRx N.V.

InflaRx is a biopharmaceutical company based in Jena, Germany, that develops treatments aimed at blocking C5a, a protein that drives inflammation. Its approved product, vilobelimab, is given intravenously and is sold in the U.S. under the name GOHIBIC, where hospitals can order it for critically ill COVID-19 patients. Its lead candidate, izicopan, is taken by mouth and is being studied for chronic skin conditions such as hidradenitis suppurativa and chronic spontaneous urticaria.

Headquarters
Jena, Germany